NEW YORK: equities started the reporting week to February 13 with a bout of profit-taking in oil stocks, but were then boosted by a range of news, leaving the Dow Jones up 0.8% overall. Pharmaceutical and biotechnology stock were generally lower, with 18 of those tracked rising and 25 falling.
The news on February 8 that drugs giant Pfizer was considering the sale of its consumer health care business boosted that stock 5% and fueled rises in others such as Johnson & Johnson and Procter & Gamble. However, Pfizer disappointed the market with its presentation to analysts ahead of the weekend, when it fell 2.5% after forecasting 2006 profits below consensus expectations (see page 3), but was still up 1.9% overall. Genentech plunged 7.0% on the news that Swiss majority owner Roche was suspending a Phase III clinical trial of its cancer drug Avastin (bevacizumab) due to safety concerns (see page 21). While most analysts felt there was no immediate concern for alarm, the drop in the stock price indicated the value that investors put on increasing sales of the drug and its relationship to Genentech's growth prospects. Baxter stock rose 3.7% on positive news from a clinical trial for Hylenex, a liquid injectable formulation that includes recombinant human hyaluronidase. Forest's stock fell 4.3%, as investors absorbed the effect of two recent marketing deals that will mean lower earnings in this year's fourth quarter and the fiscal year ending March 1. The agreements call for upfront payments to two companies during the quarter, which will boost Forest's R&D expenses to $405.0 million from $285.0 million. The payments are booked as R&D expenses because the drugs covered in these transactions are still experimental.
Cost-cutting through layoffs and plant closures will not solve the drug sector's problems long-term, according to analysts, who are skeptical of companies taking this route. The real problem is a lack of new blockbusters to offset generic competition and drugs withdrawn for safety reasons, they note, all agreeing that this is a very tough time. What firms need to do is increase R&D spending, to create value with innovative new products, they say.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
An ophthalmic gene therapy company aiming to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
Stock Commentary - New York week to Feb 13, 2006
NEW YORK: equities started the reporting week to February 13 with a bout of profit-taking in oil stocks, but were then boosted by a range of news, leaving the Dow Jones up 0.8% overall. Pharmaceutical and biotechnology stock were generally lower, with 18 of those tracked rising and 25 falling.
The news on February 8 that drugs giant Pfizer was considering the sale of its consumer health care business boosted that stock 5% and fueled rises in others such as Johnson & Johnson and Procter & Gamble. However, Pfizer disappointed the market with its presentation to analysts ahead of the weekend, when it fell 2.5% after forecasting 2006 profits below consensus expectations (see page 3), but was still up 1.9% overall. Genentech plunged 7.0% on the news that Swiss majority owner Roche was suspending a Phase III clinical trial of its cancer drug Avastin (bevacizumab) due to safety concerns (see page 21). While most analysts felt there was no immediate concern for alarm, the drop in the stock price indicated the value that investors put on increasing sales of the drug and its relationship to Genentech's growth prospects. Baxter stock rose 3.7% on positive news from a clinical trial for Hylenex, a liquid injectable formulation that includes recombinant human hyaluronidase. Forest's stock fell 4.3%, as investors absorbed the effect of two recent marketing deals that will mean lower earnings in this year's fourth quarter and the fiscal year ending March 1. The agreements call for upfront payments to two companies during the quarter, which will boost Forest's R&D expenses to $405.0 million from $285.0 million. The payments are booked as R&D expenses because the drugs covered in these transactions are still experimental.
Cost-cutting through layoffs and plant closures will not solve the drug sector's problems long-term, according to analysts, who are skeptical of companies taking this route. The real problem is a lack of new blockbusters to offset generic competition and drugs withdrawn for safety reasons, they note, all agreeing that this is a very tough time. What firms need to do is increase R&D spending, to create value with innovative new products, they say.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze